The dilemma of prostate-specific antigen testing.
Robin
R
Leach
Ian M
IM
Thompson
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000368:Aged; D000951:Antigens, Neoplasm / Q000652:urine; D014408:Biomarkers, Tumor / Q000097:blood* / Q000652:urine; D001706:Biopsy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy / Q000379:methods; D003657:Decision Making; D051517:Digital Rectal Examination; D018450:Disease Progression; D055088:Early Detection of Cancer; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000652:urine; D010358:Patient Participation; D011159:Population Surveillance; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018570:Risk Assessment; D012307:Risk Factors
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D015514:Oncogene Proteins, Fusion; C515553:TMPRSS2-ERG fusion protein, human; C479341:prostate cancer antigen 3, human; D017430:Prostate-Specific Antigen